How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

681 results for


Latest & greatest

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

81. Enzyme Kinetics and Molecular Docking Studies on Cytochrome 2B6, 2C19, 2E1, and 3A4 Activities by Sauchinone Full Text available with Trip Pro

key amino acid residues in the active site of CYP2B6, 2C19, 2E1, and 3A4. When sibutramine, clopidogrel, or chlorzoxazone was co-administered with sauchinone to mice, the systemic exposure of each drug was increased compared to that without sauchinone, because sauchinone reduced the metabolic clearance of each drug. In conclusion, when sauchinone was co-treated with drugs metabolized via CYP2B6, 2C19, 2E1, or 3A4, sauchinone-drug interactions occurred because sauchinone inhibited the CYP-mediated

2018 Molecules : A Journal of Synthetic Chemistry and Natural Product Chemistry

82. Pharmacokinetics of Simvastatin Post Laparoscopic Sleeve Gastrectomy (LSG)

, carbamazepine, rifampicin, ketoconazole, fluconazole, itraconazole, voriconanzole, diltiazem, verapamil, dexamethasone, prednisolone, phenytoin, ritonavir, indinavir, nelfinavir, bosentan, telithromycin, nefazodone, St John's wort, orlistat, sibutramine and other strong CYP 3A4 inhibitors/ inducers Pregnant ladies Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information

2018 Clinical Trials

83. Drugs Involved in Dyslipidemia and Obesity Treatment: Focus on Adipose Tissue Full Text available with Trip Pro

, involved in the pathogenic mechanisms underlying this syndrome. We revised the effects, and underlying mechanisms, of the current approved drugs for dyslipidemia and obesity (fibrates, statins, niacin, resins, ezetimibe, and orlistat; sibutramine; and diethylpropion, phentermine/topiramate, bupropion and naltrexone, and liraglutide) on adipose tissue. Specifically, we explored how these drugs can modulate the complex pathways involved in metabolism, inflammation, atherogenesis, insulin sensitivity

2018 International journal of endocrinology

86. Guidelines for the Primary Prevention of Stroke: A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association

lifestyle goals, including normal weight, were met. 279 The Sibutramine Cardiovascular Outcomes (SCOUT) trial followed up 10 000 patients with CVD or type 2 diabetes mellitus and found that even modest weight loss reduced cardiovascular mortality in the following 4 to 5 years. 280 Reduction in body weight improves control of hypertension. A meta-analysis of 25 trials showed mean SBP and DBP reductions of 4.4 and 3.6 mm Hg, respectively, with a 5.1-kg weight loss. 281 The US Preventive Services Task

2014 American Heart Association

88. Observational study: Metformin associated with better cardiovascular outcomes than other glycaemic therapies

glycaemic therapies Zachary T Bloomgarden Statistics from Context A question exists as to whether the outcome of glycaemic treatment of diabetes varies with the agent used; speculation surrounds whether metformin might be preferable to other treatments. Methods Ghotbi and colleagues performed an epidemiological analysis of 8192 obese patients with diabetes at increased cardiovascular risk participating in the Sibutramine Cardiovascular OUTcomes (SCOUT) trial. Mortality and a combined (...) cardiovascular outcome of non-fatal myocardial infarction, non-fatal stroke, resuscitation after cardiac arrest or cardiovascular death were compared among those receiving one of the following interventions: no pharmacological glycaemic treatment, metformin monotherapy, insulin monotherapy, sulfonylurea monotherapy, metformin plus sulfonylurea and metformin plus insulin. Each group consisted of approximately 1000–1500 participants, randomised to either sibutramine or control (the main purpose of the trial

2014 Evidence-Based Medicine

93. Overweight and Obesity in Adults: Guideline For the Management of

K, Sundström J, Neovius K, et al. Long-term changes in blood pressure following orlistat and sibutramine treatment:a meta- analysis. Obes Rev 2010;11:777–91. 22. Look AHEAD Research Group, Pi-Sunyer X, Blackburn G, et al. Reduction in weight and cardiovascular disease risk factors in in- dividuals with type 2 diabetes: one-year results of the Look AHEAD trial. Diabetes Care 2007;30:1374–83. 23. Look AHEAD Research Group, Wing RR. Long-term effects of a lifestyle intervention on weight

2013 American College of Cardiology

95. Centrally-acting drugs for obesity cause more harm than good

products (16 trials with 24,555 participants) – three (lorcaserin, naltrexone-bupropion and phentermine-topiramate ) of which are currently available and two (rimonabant and sibutramine) withdrawn from the market because of serious adverse reactions. Centrally acting medicines increased the chance of losing at least 5% of body weight, but their use was associated with increased risk of harms and discontinuation because of these harms. In particular, the risk of nervous and psychiatric adverse events

2018 Evidence-Based Medicine blog

97. A Phase IV Study in Drug-Naive Patients With T2DM in China

affect the interpretation of efficacy or safety data. History of bone fracture secondary to diagnosed severe osteoporosis. Currently unstable or serious cardiovascular, renal, hepatic, hematologic, oncologic, endocrine, psychiatric, or rheumatic diseases as judged by the Investigator. Replacement or chronic systemic corticosteroid therapy, defined as any dose of systemic corticosteroid taken for >4 weeks within 3 months before enrollment visit. Administration of sibutramine, phentermine, orlistat

2017 Clinical Trials

98. Exogenous T3 toxicosis following consumption of a contaminated weight loss supplement Full Text available with Trip Pro

a weight loss product online from India which supposedly contained sibutramine. He provided one of the tablets and laboratory analysis confirmed the presence of T3 in the tablet. Full symptomatic resolution and normalised thyroid function ensued upon discontinuation of the supplement.Free tri-iodothyronine (T3) measurement may be useful in the presence of symptoms suggestive of thyrotoxicosis with discordant thyroid function tests.Thyroid uptake scanning can be a useful aid to differentiating exogenous

2017 Endocrinology, diabetes & metabolism case reports

99. Ferulic acid lowers body weight and visceral fat accumulation via modulation of enzymatic, hormonal and inflammatory changes in a mouse model of high-fat diet-induced obesity Full Text available with Trip Pro

male Swiss mice, weighing 20-25 g (n=6-8 per group) were fed a normal diet (ND) or HFD, treated orally or not with either FA (10 mg/kg) or sibutramine (10 mg/kg) for 15 weeks and at the end of this period, the body weights of animals, visceral fat accumulation, plasma levels of glucose and insulin hormone, amylase and lipase activities, the satiety hormones ghrelin and leptin, and tumor necrosis factor-α (TNF-α) and monocyte chemoattractant protein-1 (MCH-1) were analyzed. Results revealed that FA (...) could effectively suppress the HFD-associated increase in visceral fat accumulation, adipocyte size and body weight gain, similar to sibutramine, the positive control. FA also significantly (P<0.05) decreased the HFD-induced elevations in serum lipid profiles, amylase and lipase activities, and the levels of blood glucose and insulin hormone. The markedly elevated leptin and decreased ghrelin levels seen in HFD-fed control mice were significantly (P<0.05) reversed by FA treatment, almost reaching

2017 Brazilian Journal of Medical and Biological Research

100. Effect of Combined Morphine and Duloxetine on Chronic Pain

, lithium, linezolid, tramadol (Ultram), St. John's Wort, central nervous system (CNS) stimulants such as amphetamine, methylphenidate, methamphetamine, phentermine, diethylpropion, sibutramine, cocaine, or thioridazine. Subject has uncontrolled narrow-angle glaucoma. Subject has sensory deficits on arms or Raynaud's Syndrome. Subject has a pending litigation related to chronic pain condition. Subject is on methadone or suboxone treatment for addiction. Contacts and Locations Go to Information from

2017 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>